Market Overview

Goldman Sachs Downgrades Myriad Genetics, Inc. to Neutral, Lowers PT to $26.00

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Latest Ratings for MYGN

DateFirmActionFromTo
Aug 2014Credit SuisseMaintainsNeutral
Jun 2014MacquarieMaintainsNeutral
May 2014Credit SuisseMaintainsNeutral

View More Analyst Ratings for MYGN
View the Latest Analyst Ratings

Posted-In: News Downgrades Analyst Ratings

 

Related Articles (MYGN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters